152 related articles for article (PubMed ID: 15942483)
1. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
2. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
[TBL] [Abstract][Full Text] [Related]
3. Relationship between estimated glomerular filtration rate and biological half-life of 131I. Retrospective analysis in patients with differentiated thyroid carcinoma.
Vogel K; Opfermann T; Wiegand S; Biermann J; Busch M; Winkens T; Freesmeyer M
Nuklearmedizin; 2013; 52(5):164-9. PubMed ID: 23821288
[TBL] [Abstract][Full Text] [Related]
4. Management of the helpless patient after radioiodine ablation therapy - are we being too strict?
Williams CE; Woodward AF
Nucl Med Commun; 2005 Oct; 26(10):925-8. PubMed ID: 16160653
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
7. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
8. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
10. A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment.
Azizmohammadi Z; Tabei F; Shafiei B; Babaei AA; Jukandan SM; Naghshine R; Javadi H; Nabipour I; Assadi M; Asli IN
Hell J Nucl Med; 2013; 16(2):103-6. PubMed ID: 23687641
[TBL] [Abstract][Full Text] [Related]
11. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
12. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
13. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
14. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
15. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
16. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
17. Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy.
Jeong KH; Jung JW; Kim CB; Ahn BC; Lee HK; Yoo SJ; Day O; Lee JK
Health Phys; 2014 Apr; 106(4):466-74. PubMed ID: 24562067
[TBL] [Abstract][Full Text] [Related]
18. Potential third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases.
D'Alessio D; Giliberti C; Benassi M; Strigari L
Health Phys; 2015 Mar; 108(3):319-25. PubMed ID: 25627943
[TBL] [Abstract][Full Text] [Related]
19. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
20. Assessment of radioiodine clearance in patients with differentiated thyroid cancer.
Tabei F; Neshandar Asli I; Azizmohammadi Z; Javadi H; Assadi M
Radiat Prot Dosimetry; 2012 Dec; 152(4):323-7. PubMed ID: 22562954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
